Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
This product is not intended to diagnose, treat, prevent or cure any disease
The absolute difference in liver fat content [LFC] was 4.7% (95% CI from 6.7 to 2.7), with a relative decrease in LFC from baseline of 35.9% and 28.4% for the two individual dosages ( p 40%, renal death, new onset of macroalbuminuria) strongly favored tirzepatide (HR 0.58, 95% CI from 0.43 to 0.80, p = 0.0008)
The overlapping GLP-1 activation would significantly increase the risk of severe gastrointestinal side effects and potentially dangerous hypoglycemia
Initially, it was only approved for diabetes management with the brand name Victoza
US$ 24.98
US$ 28.78
US$ 23.23
US$ 28.83
US$ 24.04
US$ 26.14
US$ 27.28
US$ 22.36
US$ 22.14
